appoints Camilla Soenderby to the board of directors by F2G Soendingby is appointed to board board members
A medical-stage biopharmaceutical company focused on rare life-threatening fungal diseases with urgent medical need, today announced the appointment of Camilla Soenderby, a non-executive director with immediate effect.
Camilla Soenderby is an experienced biopharma executive with 20 years of international experience from strategic and operational roles across the EU, the US and Asia scale. Her reputation of developing and growing businesses has led numerous worldwide cross-functional teams to drive portfolio strategy and commercialisation of treatments for rare diseases, oncology and specialty ailments.
Patrick Vink, CEO of F2G Ltd., Mr. Vin K.V. , said said. "On behalf of the whole board I'm very pleased to welcome Camilla to F2G. She is a highly successful building and commercialising global brands. Her experience complements the management team's experience as we advance our lead product, olorofim, towards commercialisation."
Camila Soenderby, Deputy Director of F2G, said: "It's impossible to tell the truth" "I'm very excited to join F2G and bring my experience to support the commercialisation of such a important product as olorofim, - if approved by the FDA, for the treatment of serious fungal This has enormous potential to treat patients with life-threatening rare diseases and address high medical needs."
Francesco Maria Lavino, CEO of F2G Ltd., Francessco Marietta, is the CEO. , added the addition of a t-shirt. "Camilla's experience and successful track record in rare diseases will be invaluable as we look to maximise the potential of olorofim. We are focused on accelerating the development of our lead asset and are targeting a NDA filing in 2022. This is a great time for F2G, as we drive the business to the next phase of growth.
At the start of her career, Camilla worked as an executive director at Takeda, where she led the global business, with a focus on the biopharmaceutics, and the medical industry.
About Olorofim / Clinical trial of the study, compared with Clinical trials.
The Phase 2 study for olorofim (ClinicalTrials.gov Identifier: NCT03583164) is a global open-label study in patients with limited treatment options for difficult-to-tre
About F2G about the cost of food.
F2G is a world-leading biotech company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G discovered and developed a completely new class of antifungal agents called orotomides. The orotomides selectively target the fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway. This is a completely different mechanism than the currently marketed antifungal agents and gives orotomides fungicides faicide against dozens of rare and resistant fungal mold infections. Olorofim (formerly F901318) is the leading candidate for the F2G class and is in a Phase 2b open-label study focusing on rare and resistant fungal infections such as aspergillos Olorofim has received orphan drug status from the European Medicines Agency for the treatment of invasive aspergillosis and scedosporiosis. Olorofim received orphan drug status from the US FDA for a treatment of coccidioidomycosis, lomentosporiosis/scedosporis and invasive aspergil Olorofim has been granted the Qualified Infectious Disease Product (QIDP) designation for invasive aspergillosis, scedosporiosis and arachosis n
SOURCE F2G SESSION SURCE